age 70 years or older, 35 nontrauma reason for the procedure, 19, 32 and high American Society of Anesthesiologists (ASA) score. 20 Procedure-related risk factors include emergency procedure, 17 no antimicrobial prophylaxis, 19 longer procedure duration, 12, 14, 18, 19 postoperative CSF leakage, [17] [18] [19] 35 and early reoperation. 17, 19, 30, 32 However, inclusion criteria for these studies varied and most studies evaluated specific subgroups of patients (for example, elective procedures) or specific infections (such as meningitis). Additionally, some studies did not assess potentially important risk factors such as comorbidities, skin preparation, and antimicrobial prophylaxis. Three studies assessed postoperative outcomes of SSIs after CRANI, but the investigators did not adjust for patients' preexisting conditions. 16, 26, 30 At the University of Iowa Hospitals and Clinics (UIHC), the SSI rates after CRANI procedures ranged from 2.6% (low risk) to 5.2% (high risk). We previously found that procedures begun before the skin antiseptic dried and procedures during which Gliadel wafers (Arbor Pharmaceuticals, Inc.) were implanted were associated with an increased risk of SSIs. 5 However, we did not evaluate some potential risk factors for SSIs and we did not evaluate outcomes. Thus, we performed this nested case-control study to 1) identify risk factors for SSIs after CRANI, 2) develop a preoperative SSI risk index, and 3) evaluate patient outcomes attributed to SSIs after CRANI.
Methods

Study Population
We studied patients undergoing CRANI in the UI-HC's Department of Neurosurgery from January 1, 2006, through December 31, 2010. We excluded patients who had infections at the time of their CRANI or who died within 2 days after CRANI. Patients were included once if they had undergone 1 or more procedures. We included all patients with infections meeting the National Healthcare Safety Network (NHSN) definition of SSI (cases). 7 We selected 312 controls from the patients without SSIs who had ≥ 1 follow-up visit or phone call. We frequency matched controls to cases by procedure period (6 months/ period) so that cases and controls were distributed equally over 10 procedure periods. For outcome analyses, we included patients undergoing CRANI from January 1, 2006, through June 30, 2010; a general internist (A.S.K.) reviewed their preoperative notes and assigned McCabe and Jackson severity of illness scores.
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Data Collection
The CRANI procedures were identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure codes (Appendix Table 1 ). We retrospectively collected data from patients' medical records regarding SSIs, potential risk factors for SSIs (Appendix Table 2 ), duration of hospitalization, readmissions, and reoperations at the UIHC, which were related to complications of the initial CRANI procedures and occurred during the 1st postoperative year. We entered the data directly into a Microsoft Access database and validated the data entry.
Data Analysis
We analyzed de-identified data using SAS software (version 9.3, SAS Institute, Inc.). We performed bivariate analyses to test the association between each potential risk factor and SSIs and the association between SSIs and each outcome. We used univariate logistic regression modeling to assess the association between SSIs and quantitative risk factors and the chi-square test or Fisher's exact test for categorical variables.
To identify factors significantly associated with SSIs, we put all factors with p < 0.15 in the bivariate analyses or with a priori clinical significance into a multivariate logistic regression model. We used backward elimination to identify factors for a final multivariate model; factors with p < 0.15 were included in the final model. We then tested clinically relevant 2-way interactions for potential inclusion. We assessed collinearity of the quantitative variables by examining the Pearson correlation coefficient between pairs of variables, and we evaluated multicollinearity by computing the variance inflation factor for each variable. To assess the predictive ability of the final multivariate model to discriminate between cases and controls, we computed the c-statistic using both the conventional method and a cross-validation method. 33 We used the Hosmer-Lemeshow goodness-of-fit test to assess the adequacy of the model fit.
We computed Kaplan-Meier estimates of the survival functions for each outcome, and we used the log-rank test to compare time-to-event curves for cases and controls. The time to the postoperative outcome (that is, event) was calculated from the date the CRANI was done to the date the postoperative outcome occurred. For readmission and reoperation, we evaluated patients who survived their 1st postoperative year and considered patients who did not have one of these outcomes within 1 year after the CRANI as censored observations. For postoperative death, we considered patients who survived 1 year after the initial CRANI as censored observations. We evaluated outcomes attributed to SSIs with multivariate linear regression (for length of stay [LOS]) or logistic regression (for readmission, reoperation, and death) to control for patients' preexisting conditions and for procedure period. Although controls were frequency matched to cases based on procedure period, we checked for possible residual confounding by considering it in the bivariate analyses. Procedure period was included as a covariate in the multivariate outcome model when the corresponding bivariate association was such that p < 0.15. Length of stay was log-transformed to meet the normality assumption.
Ethics Approval
The institutional review board at the University of Iowa Carver College of Medicine approved the study.
Results
Risk Factor Study
During the study period, neurosurgeons performed 2919 CRANI procedures in 2541 patients, of whom 104 (4.1%) acquired SSIs. We selected 312 patients without SSIs as controls. Table 3 ). Gramnegative organisms alone (15.4%) or in combination with other organisms (11.5%) caused 26.9% of the SSIs.
Patients and controls were similar with respect to numerous demographic, preoperative, and operative variables (Table 1) . Compared with controls, patients with SSIs were more likely to have worse comorbidity scores, previous brain operations, chemotherapy on admission, preoperative glucose levels ≥ 100 mg/dl, nontrauma reason for the CRANI procedure, longer preoperative hospitalizations, an NHSN risk score ≥ 2, bone flaps fixed with plates and screws (that is, rigid plated), Gliadel wafer implants, and postoperative CSF leaks.
In the multivariate model, preoperative LOS ≥ 1 day was the only preoperative risk factor for SSIs that was significant ( Table 2 ). Any previous brain operation, chemotherapy on admission, nontrauma procedure reason, and a preoperative glucose level ≥ 100 mg/dl were marginally associated with increased risk of SSIs (p ≤ 0.10). We used 100 mg/dl as the cut point for glucose level because it had the highest odds ratio and the lowest p value among the 3 cut points (that is, 100, 120, and 150 mg/ dl) considered in the bivariate analysis. The preoperative model had fair predictive efficacy (c = 0.663; crossvalidated c = 0.607). The overall model, which included both patient-related and procedure-related factors, identified preoperative LOS ≥ 1 day, Gliadel wafer implants, and postoperative CSF leakage as factors that achieved significance at the 0.05 level (Table 3) . Chemotherapy on admission, preoperative glucose level ≥ 100 mg/dl, and procedure duration > 225 minutes (the duration cut point for the NHSN risk index) 3 were marginally associated with increased risk of SSIs (p ≤ 0.10). The overall model had good predictive efficacy (c = 0.716; cross-validated c = 0.677).
To develop a preoperative SSI risk index, we multiplied regression coefficient estimates from the preoperative model by 10 and rounded them to establish the points assigned for each risk factor ( Table 2 ). The risk points for each factor were added to obtain the risk score, which predicted SSIs significantly better (c = 0.664; cross-validated c = 0.622) than the NHSN risk index (c = 0.547; p = 0.004) (Fig. 1) . We categorized patients into 3 risk classes based on cut points that provided the highest c-statistic (Table 4) . Patients in risk Class 2 or 3 had an increased risk of SSI over those in risk Class 1. Our risk index categorized 28% of cases and 8% of controls in the high-risk group (Class 3) compared with 24% of cases and 15% of controls for NHSN's risk index (Class 2 or 3).
Outcome Study
The outcome study included 93 cases and 279 controls who underwent CRANI between January 1, 2006, and June 30, 2010. On average, relative to controls, patients with SSIs received antimicrobial agents on more days after CRANI during their initial hospitalizations and had longer hospital LOS during either initial hospitalizations or readmissions (Table 5) . Because LOS was log-transformed and analyzed by linear regression, we should interpret the results as the multiplicative LOS increase in average LOS attributed to SSIs. For example, a multiplicative increase of 1.4 for LOS during the initial hospitalization indicated that an SSI will attribute to a 40% increase in the average LOS. Patients with SSIs were more likely than controls to have ≥ 2 readmissions, to have ≥ 2 reoperations to treat complications, and to die within 1 year after their procedures ( Table 5 ).
The time from the CRANI to hospital discharge was ≥ 20 days for about 25% of cases and 15% of controls ( Fig. 2A ; p = 0.04). Among patients who survived ≥ 1 year, about 45% of cases and 15% of controls were readmitted within 50 days after their procedures ( Fig. 2B ; p < 0.0001), and about 65% of cases and 15% of controls had reoperations within 50 days of their procedures ( Fig.  2C ; p < 0.0001). Time-to-event curves assessing the time from the CRANI to death were different, but we did not compare the 2 curves because they crossed around the 100th postoperative day (Fig. 2D ). Before the 100th day, the probability of survival was higher for cases than controls; thereafter, the probability of survival was higher for controls than cases. Acute medical conditions may have increased the risk of early death among controls because controls were more likely than cases to have head trauma or intracranial bleeding (34% vs 24%). We did a subgroup analysis by indication for procedure. Among patients with acute conditions of trauma or intracranial bleeding, the time-to-event curves of cases and controls did not cross and they were not significantly different (log-rank test, p = 0.87). Among patients with other indications, the 2 curves crossed at the 100th postoperative day, but the curves were almost identical before that. Cases were more likely than controls to die after the 100th postoperative day.
Among 93 cases and 279 controls included in the outcome study, cases were more likely than controls to have longer preoperative LOS (2.1 ± 4.2 days vs 1.0 ± 2.7 days; p = 0.02), Charlson comorbidity indices ≥ 2 (54.8% vs 41.6%; p = 0.03), 4 and nontraumatic reasons for CRANI (90.3% vs 78.1%; p = 0.009). Older age and worse McCabe and Jackson severity of illness scores were not significantly associated with SSIs. However, these factors could be clinically important. Thus, we included these factors and procedure month period in the multivariate models for each outcome to control for potential confounding effects. Compared with controls, patients with SSIs tended to remain in the hospital longer during their initial visits and during readmissions (Table 6 ). Surgical site infections were associated with an increased risk of readmission, reoperation, and postoperative death. 
Discussion
This study is unique in that we used robust analytical methods to assess risk factors and outcomes for all SSIs after all CRANI procedures. We comprehensively evaluated many risk factors for SSIs, controlled for potential confounding in multivariate analyses, and used appropriate analyses to evaluate postoperative outcomes of SSIs. Therefore, compared with previous studies, our study should provide less biased association estimates for risk factors and outcomes potentially related to SSIs after CRANI.
Patient-Related Risk Factors
Preoperative LOS was the only significant patientrelated risk factor identified in the multivariate model. In contrast, studies by Korinek et A history of previous brain operation, chemotherapy on admission, and preoperative glucose level achieved the significance level in our bivariate analyses but not in the multivariate analysis. However, these variables are clinically important. Moreover, Korinek's multivariate analysis found that a neurosurgical procedure in the 30 days before CRANI increased the risk of SSIs. 17 In our study, patients who underwent CRANI to treat brain tumors were more likely than patients who underwent CRANI for other reasons to be on a chemotherapy regimen at admission and they had an increased risk of acquiring SSIs. Thus, the procedure reason could be an effect modifier for the association between other preoperative risk factors and SSIs. However, none of the interaction terms for the procedure reason and other preoperative factors was significant. Thus, the procedure reason did not modify the manner in which prolonged preoperative LOS, previous brain operation, and chemotherapy on admission were associated with an increased risk of SSIs.
Patients who have neurosurgical procedures often receive corticosteroids, which may elevate their glucose levels. Most prior studies have not found an association between diabetes or hyperglycemia and SSIs after neurosurgical procedures. 9, 20, 24, 30 Glycemic control has been associated with SSI rates after coronary artery bypass procedures. 11,21 Diabetes was not a risk factor for SSIs in our study but a preoperative glucose level ≥ 100 mg/dl was marginally associated with a 1.6-fold increase in the odds of SSIs. Given that glucose levels are modifiable, further study of this potential risk factor is warranted.
Procedure-Related Risk Factors
Our overall model indicated that procedure-related factors were more strongly associated with SSIs than were patient-related factors. Gliadel wafer implants were the strongest risk factor for SSIs even after adjusting for chemotherapy on admission. We previously found an 8.4-fold increase in the odds of SSIs associated with Gliadel wafers, and Subach et al. found a 13.5-fold increase in the odds.
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However, Attenello et al. and Brem et al. did not find increased SSI rates associated with these implants. 1, 3 The differing results may be related, in part, to differences in study populations and to the fact that previous investigators did not account for potential confounders such as steroids, chemotherapy, or radiation therapy. The UIHC's neurosurgeons used Gliadel wafers in patients with advancedstage brain tumors (for example, recurrent glioblastoma). Patients with Gliadel wafers were more likely than those without wafer implants to have Charlson comorbidity indices ≥ 2 (100% vs 41%; p < 0.0001) and McCabe and Jackson scores of fatal (100% vs 44%; p < 0.0001) and, thus, may have had increased risk for SSIs. We did not collect data on the tumor stage (for example, recurrent high-grade glioma), but we might have controlled for some confounding effect by including chemotherapy on admission in the overall multivariate model. Our neurosurgeons thought that most patients who received Gliadel wafers and subsequently acquired SSIs required multiple procedures to treat the infections and had bad outcomes. On the basis of both our results and their own experiences, our neurosurgeons significantly decreased Gliadel wafer use. However, we should not conclude that Gliadel wafers directly caused the SSIs because association did not establish causation. Similar to our study, Korinek alone and with colleagues and Shinoura et al. found that CSF leakage increased the risk of SSIs after CRANI, [17] [18] [19] 35 whereas Kourbeti et al. found that CSF leakage was not associated with meningitis after CRANI. 20 Special surgical techniques, 13, 27 synthetic absorbent sealants to close the wound or dura mater, 10, 37 or draining CSF during procedures 25 may help prevent CSF leakage. Most of these interventions were used during procedures to remove pituitary tumors 25 or vestibular schwannomas, 13 and these methods may not be appropriate for other CRANI procedures. Like Gliadel wafers, CSF leakage might not cause SSIs. Instead SSIs and CSF leakage may both be measures of impaired wound healing. Future studies of techniques for obtaining watertight skin closures or for sealing the dura should assess whether they prevent CSF leakage and whether they prevent SSIs after CRANI.
Surgical Site Infection Risk Index
A risk index consisting of patient-related factors can help neurosurgeons identify patients at high risk for SSIs and allow infection preventionists to stratify patients' intrinsic risk of SSIs so they can compare SSI rates between hospitals or surgeons. The NHSN risk index had low efficacy in predicting whether patients would acquire SSIs after CRANI because the 3 factors (ASA score, wound contamination class, and operation duration) in the NHSN risk index often are not associated with SSIs after CRANI. 5, 17, 19, 32 Sánchez-Arenas and colleagues' risk index, which included the presence of chronic disease and nontrauma as the procedure reason, had better predictive discrimination than the NHSN risk index (c = 0.625 vs c = 0.558). 32 However, this risk index may not be generalizable because the study did not include patients who received implants. Our risk index's predictive efficacy was superior to that of the NHSN risk index. Moreover, neurosurgeons could use it to determine the a priori risk of an SSI, regardless of the reason for the CRANI procedure. The cross-validated c-statistic (0.622) suggests how the index might perform on a validation sample. But this preoperative SSI risk index should be validated in another large patient population before it is applied widely.
Postoperative Outcomes
Studies by Kasatpibal et * Statistics are number of patients (%) or mean ± SD. † Quantitative outcomes were log-transformed and analyzed by univariate linear regression. ‡ Postoperative antimicrobial days excluding the first 2 days after the procedure during the initial hospitalization. § Readmissions and reoperations were evaluated for 69 cases and 239 controls who survived the 1st postoperative year.
died in the hospital but no control patient died. 30 However, these analyses were not controlled for some possible confounders. Thus, bias may have affected their results. Unlike prior studies, we performed multivariate analyses to assess whether SSIs were associated with postoperative outcomes after adjustment for covariates that were potentially associated with these outcomes. We found that SSIs were associated with significantly prolonged LOS during initial hospitalizations and readmissions and with significantly increased risk of readmission, reoperation, and death. Similarly, our previous study found that 85% of patients with SSIs required additional operations to treat infections. 
Organisms Causing Surgical Site Infections
Staphylococcus aureus caused almost one-third of SSIs after CRANI, similar to the published finding that S. aureus caused 14%-51% of SSIs. 5, [17] [18] [19] Nasal carriers of S. aureus are at increased risk for S. aureus SSIs, 28, 38, 39 and studies of other surgical specialties have shown that screening for S. aureus nasal carriage and decolonizing carriers significantly decreased S. aureus SSIs. 2, 29, 31, 34 A recent meta-analysis suggested that a bundle including screening for S. aureus nasal carriage, decolonizing carriers with mupirocin ointment, and chlorhexidine bathing before procedures reduced S. aureus SSIs. 34 However, no published study has evaluated the effectiveness of S. aureus decolonization in reducing SSIs after neurosurgical procedures. A well-designed, quasi-experimental study using time-series analysis or a randomized clinical trial assessing the effectiveness of S. aureus decolonization in decreasing SSIs after CRANI would be a valuable contribution to the literature.
Gram-negative bacteria, which usually are not part of the normal skin flora, caused over 25% of SSIs. These infections could potentially be prevented by administering prophylactic agents that cover gram-negative bacteria. In our study, more than half of the patients received prophylaxis with nafcillin alone (49%) or in combination with other agents that cover gram-positive bacteria (5%), and 30% of patients received vancomycin alone (13%) or in combination with other agents that cover gram-positive bacteria (17%). Unlike cefazolin, the agent recommended for perioperative prophylaxis, these agents are not active against gram-negative bacteria. In our unpublished study of spinal operations, we found an increased risk of SSIs for patients receiving nafcillin or vancomycin as prophylaxis (Behen AZ, Pottinger JM, Chiang HY, et al: Risk factors for surgical site infections after spine operations. Presented at the 21st Annual Scientific Meeting of Society for Healthcare Epidemiology of America, 2011). On the basis of these observations, neurosurgeons at the UIHC began using cefazolin for all neurosurgical patients who are not allergic to cefazolin and who do not carry methicillin-resistant S. aureus. We are monitoring to determine if changing the prophylactic agent has decreased the SSI rate.
Study Limitations
This study has several limitations. First, we did not actively follow up on patients and we collected data from medical records. Thus, we might have missed patients who acquired SSIs or other adverse outcomes but did not seek care at the UIHC. Most patients who acquired SSIs should have been captured by our surveillance because infection preventionists at other hospitals in Iowa usually inform the UIHC's infection preventionists if patients who had operations at the UIHC are admitted with SSIs to their hospitals. Additionally, our neurosurgeons follow up on patients for at least 3 months, and most patients with serious surgical complications are referred back to the UIHC. Thus, we believe that the undetected outcomes were likely to have been minor and were likely to have occurred among patients without SSIs, which could have caused us to overestimate outcomes attributed to SSIs. Second, we did not match cases and controls by the indication for procedure, which makes it difficult to interpret the time-to-event curve for postoperative death. Acute conditions of trauma or intracranial bleeding might have attributed to early death among controls. When we completed a subgroup analysis for patients with acute conditions, the time-to-event curves of cases and controls did not cross and were not significantly different. For patients with other indications, the 2 curves remained to be crossed at the 100th postoperative day, but unlike the curves for all patients, they were very similar before the 100th postoperative day. The subgroup analyses revealed that the association between SSIs and postoperative death could be affected by the indication of the procedure, which should be taken into account when doing survival analysis for patients undergoing CRANI. Third, we did not validate the study results in another patient cohort. The patients admitted to the UIHC tend to have more severe medical conditions than patients admitted to community hospitals because the UIHC is a quaternary care, referral medical center. Therefore, our results may not be generalizable and should be validated in other patient populations.
Conclusions
Procedure-related factors were the strongest predictors of SSIs. Most patient-related risk factors reflect the patients' intrinsic risk of SSIs, which may be difficult to modify. Hyperglycemia could be modified, but further study is needed to determine if it is associated with an increased risk of SSI after CRANI. Staphylococcus aureus nasal carriage, Gliadel wafer implants, and postoperative CSF leakage may be modifiable. Given the adverse outcomes associated with SSIs and current reimbursement issues, studies of interventions to modify these risk factors could benefit patients and neurosurgery programs significantly. 
